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Abstract
Purpose The purpose of this study is to report the use of
intravitreal triamcinolone for treatment of cancer-associated
retinopathy (CAR) refractory to systemic therapy.
Methods This was a retrospective chart review study.
Results A 67-year-old man presented with cancer-
associated retinopathy with antibodies against a 46-kDa reti-
nal protein, alpha enolase. There was disease progression
despite therapy with mycophenolate and intravenous immu-
noglobulin. Serial intravitreal injections of triamcinolone
resulted in restoration of photoreceptor anatomy on optical
coherence tomography and visual improvement. The patient’s
vision was preserved at 20/40 OD and 20/32 OS until his
death from lung cancer 31 months after CAR diagnosis.
Conclusions Intravitreal triamcinolone may be beneficial
for maintenance of vision in patients with CAR.
Introduction
Cancer-associated retinopathy (CAR) is a paraneoplastic pro-
cess caused by autoantibodies against retinal proteins, includ-
ing recoverin and alpha enolase [1, 2]. Approximately 50% of
patients with CAR present with visual symptoms before the
diagnosis of a malignancy is made [3]. CAR is rare, and there
are currently no standard treatment regimens for the condition
[4]. Systemic corticosteroids, steroid-sparing immunosup-
pression, and non-traditional immunomodulatory therapies
including intravenous immunoglobulin (IVIg) have been
shown to variably preserve or improve vision [5–7]. Cystoid
macular edema (CME) has been reported in patients with non-
paraneoplastic autoimmune retinopathy (npAIR) but is less
common with CAR [2]. We report a patient with CAR in
whom serial intravitreal steroid injections resulted in mainte-
nance of visual function for more than 2 years until his death.
Case report
A 67-year-old man presented with decreased vision, photop-
sias, and nyctalopia. Examination revealed best corrected
visual acuities of 20/32 in the right eye and 20/25 in the left
eye. Dilated fundus exam was remarkable for bilateral CME
and arteriolar narrowing (Fig. 1a). Fluorescein angiography
(FA) revealed petalloid leakage at the fovea, perivascular
leakage, and disk staining bilaterally (Fig. 1b). Multifocal
and full-field electroretinography (ERG) revealed severely
decreased scotopic and photopic responses but no negative
ERG pattern. Serologic testing revealed the presence of anti-
bodies to a 46-kDa retinal protein that was confirmed to be
alpha enolase. Systemic evaluation for malignancy uncovered
poorly differentiated squamous cell carcinoma of the lung.
Chemotherapy was initiated with carboplatin and paclitaxel.
For his eye disease, the patient was initially treated with intra-
venous methylprednisolone, 1 g/day for 3 days, followed by
oral prednisone (initial dose of 80 mg/day and then a taper over
2 months) with decreased retinal vascular leakage and CME.
The patient’s visual acuities worsened to 20/125 OD and
20/60 OS with tapering of the prednisone, and FA showed
worsening retinal vasculitis. Steroid-sparing treatment was
attempted first with mycophenolate mofetil (2 g/day) and
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then with four doses of IVIg, with no response to either
therapy. FA continued to show CME and diffuse retinal
vasculitis. Intravitreal triamcinolone (IVTA) was adminis-
tered bilaterally, with vision improving to 20/40 OD and 20/
32 OS and resolution of cystic changes. Over the ensuing
2.5 years, the patient received four additional IVTA injec-
tions bilaterally. When the IVTA effect waned, his vision
diminished to as low as 20/70 in the right eye and hand
motions in the left eye. After the initial injection, there were
no retinal cystic changes or significant retinal thickening on
optical coherence tomography (OCT) at the subsequent visits,
yet the patient periodically reported visual deterioration and
had objectively diminished visual acuity with disruption of
photoreceptor anatomy on OCT (Fig. 2a). The vision and
anatomical changes improved with IVTA (Fig. 2b). His visual
acuities were 20/40 OD and 20/32 OS after the most recent
IVTA injections. The patient developed steroid response in-
traocular pressure rises in both eyes that decreased with
Fig. 1 a Fundus photos
showing macular edema and
arteriolar narrowing. b
Fluorescein angiography
showing petalloid leakage in
the macula, perivascular
leakage, and disk staining
Fig. 2 a OCT of left eye
showing loss of the inner
segment/outer segment (IS/OS)
junction subfoveally (arrow) and
hyperreflective areas along the
photoreceptor layer (arrowheads),
possibly indicative of foci of
active inflammation. The patient’s
vision was hand motions. b OCT
1 month after intravitreal steroid
injection. The IS/OS junction has
been restored subfoveally (arrow)
and the hyperreflective areas have
largely resolved, with vision
improving to 20/32
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topical antihypertensive therapy. No other complications of
IVTA injections occurred. He passed away from complica-
tions of his lung cancer 31 months after his CAR diagnosis.
Discussion
This report describes the successful treatment of CAR with
intravitreal steroids. The treatment of CAR is often challeng-
ing. Treatment of the underlying malignancy alone does not
alter the course of the ocular disease. Various treatment mo-
dalities have been tried in patients with CAR, including oral
and intravenous steroids, plasmapheresis, IVIg, rituximab,
azathioprine, cyclosporine, and mycophenolate mofetil [2,
6–8]. Despite treatment with these systemic medications, it
is not unusual to have a progressive decline in vision with this
disease. Our patient responded initially to systemic steroids
but did not have an alteration of his disease course with
mycophenolate mofetil or IVIg. After initiation of IVTA
injections, his vision improved. Vision improvement in CAR
is unusual; vision stabilization is often the best that can be
hoped for. In this patient, there was strong evidence for a
causal relationship between the injections and visual improve-
ment. When the intravitreal triamcinolone wore off, his vision
declined.With his initial injections, the improvement in vision
could be attributed, at least in part, to treatment of the CME.
But subsequent injections were given when there were no
retinal cystic changes or thickening present on OCT and yet
reinjection led to marked subjective and objective improve-
ment. The improvement was likely due to suppression of
inflammation around the photoreceptors as evidenced by res-
toration of inner segment/outer segment junction and resolu-
tion of hyperreflective lesions along the photoreceptor layer
on OCT after the injections. In one such instance, his vision
recovered from hand motions to 20/32 OS.
CME and periphlebitis can be seen in patients with
npAIR but is less common with CAR. There is one case
report of retinal periphlebitis associated with CAR in a
patient with ovarian cancer [9]. In the presence of CME,
intravitreal steroids have previously been shown to be ef-
fective in patients with npAIR [2]. The unique presentation
of CAR with CME and vasculitis in our patient motivated
the use of intraocular triamcinolone, but there was evidence
for an effect on the course of CAR directly given the visual
improvements even when IVTA injected in the absence of
CME. The presence of anti-retinal antibodies in the sera of
patients with CAR suggests the need for systemic interven-
tion in general, but this patient’s course suggests that a
subset of CAR patients might be successfully treated with
local therapy. The OCT photoreceptor findings in this pa-
tient pre- and post-injection indicate that intravitreal steroids
may be able to successfully suppress inflammation and
apoptosis induced by the autoantibodies at the level of the
photoreceptors despite ongoing systemic production and/or
circulation of antibodies. Some authors caution that readmi-
nistration of intravitreal steroid for recurrent CME in npAIR
and CAR is best done early when cystic changes are just
starting to recur to avoid cycles of retinal cyst expansion and
collapse which may cause retinal damage [2, 10]. Similarly,
CAR patients without CME being treated with intravitreal
steroids should be followed closely with OCT imaging and
retreated promptly when evidence of photoreceptor layer
disruption becomes apparent to avoid permanent photore-
ceptor damage.
In summary, intravitreal steroids should be considered in
patients with CAR who do not respond to systemic therapy.
In our patient, serial IVTA injections led to preservation of
vision for almost 3 years.
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